Current Concepts on 6-sulfo LacNAc Expressing Monocytes (slanMo)

Faried, Ahmad; Döbel, Thomas; Schmitz, Marc; Schäkel, Knut

doi:10.3389/fimmu.2019.00948

Cited by 39 publications

(38 citation statements)

References 135 publications

(257 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From animal experiments, we know that chronic UVB exposure can induce skin carcinomas and chronic solar UV exposure is clearly associated with skin carcinomas in humans . It is attractive to hypothesise that an aberrantly heightened skin immunity in psoriasis underlies this discrepancy …”

Section: The Actual Evidence For Optimal Efficacy and Safety Accordinmentioning

confidence: 99%

Phototherapy in the perspective of the chronicity of psoriasis

Kerkhof

Gruijl

2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

According to the guidelines for the treatment of psoriasis, phototherapy is given in courses of UVB exposure starting at 50-70% of the minimal erythema dose, MED, with subsequently incremental dosages, but keeping erythemal skin reactions to a minimum by restraining the dosages when necessary. In this review, this classical principle of short-term near erythematogenic UVB therapy without further UVB maintenance therapy is challenged as it is evidently not optimal for psoriasis as a chronic condition. There is old experimental evidence supplemented with growing knowledge on the mode of action of phototherapy and more recent data on low-level UVB regimens as maintenance therapy that should urge us to revisit our guidelines on phototherapy to address psoriasis for what it is: a chronic condition.

show abstract

Section: The Actual Evidence For Optimal Efficacy and Safety Accordinmentioning

confidence: 99%

Phototherapy in the perspective of the chronicity of psoriasis

Kerkhof

Gruijl

2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…However, tumor-infiltrating DCs can also be defective in their functional activity and can contribute to immune suppression (14). For example, we have shown that a higher density of 6-sulfo LacNAc monocytes (slanMo), representing a subset of human non-classical blood monocytes that can differentiate into DCs (15), is significantly associated with a poor prognosis of clear cell renal cell cancer (RCC) patients (16). The tumor-infiltrating slanMo displayed an immature phenotype and expressed IL-10, which may explain this correlation.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

The tumor immune contexture plays a major role for the clinical outcome of patients. High densities of CD45RO + T helper 1 cells and CD8 + T cells are associated with improved survival of patients with various cancer entities. In contrast, a higher frequency of tumor-infiltrating M2 macrophages is correlated with poor prognosis. Recent studies provide evidence that the tumor immune architecture also essentially contributes to the clinical efficacy of immune checkpoint inhibitor (CPI) therapy in patients. Pretreatment melanoma samples from patients who experienced a clinical response to antiprogrammed cell death protein 1 (PD-1) treatment show higher densities of infiltrating CD8 + T cells compared to samples from patients that progressed during therapy. Anti-PD-1 therapy results in an increased density of tumor-infiltrating T lymphocytes in treatment responders. In addition, elevated frequencies of melanoma-infiltrating TCF7 + CD8 + T cells are correlated with beneficial clinical outcome of anti-PD-1-treated patients. In contrast, a high density of tumor-infiltrating, dysfunctional PD-1 + CD38 hi CD8 + cells in melanoma patients is associated with anti-PD-1 resistance. Such findings indicate that comprehensive tumor immune contexture profiling prior to and during CPI therapy may lead to the identification of underlying mechanisms for treatment response or resistance, and the design of improved immunotherapeutic strategies. Here, we focus on studies exploring the impact of intratumoral T and B cells at baseline on the clinical outcome of CPI-treated cancer patients. In addition, recent findings demonstrating the influence of CPIs on tumor-infiltrating lymphocytes are summarized.

show abstract

“…Functional analysis of this interaction revealed a significantly decreased phagocytic capacity and antigen-presenting ability of monocytes and macrophages when co-cultured with UC-MSCs. Furthermore, we investigated the impact of MSCs on various immunomodulatory properties of 6-sulfo LacNAc monocytes (slanMo), representing a subset of pro-inflammatory CD14 – CD16 + non-classical monocytes, which may contribute to the pathogenesis of various inflammatory diseases ( Ahmad et al, 2019 ). We found that MSCs profoundly suppress the capacity of slanMo to secrete TNF-α, IL-6, and IL-12, improve their IL-10 production, and efficiently inhibit the slanMo-induced proliferation of CD4 + and CD8 + T cells ( Wehner et al, 2009 ).…”

Section: Modulation Of Innate Immunity By Mscsmentioning

confidence: 99%

Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update

Müller

Tunger

Wobus

et al. 2021

Front. Cell Dev. Biol.

Self Cite

110

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) are characterized by an extraordinary capacity to modulate the phenotype and functional properties of various immune cells that play an essential role in the pathogenesis of inflammatory disorders. Thus, MSCs efficiently impair the phagocytic and antigen-presenting capacity of monocytes/macrophages and promote the expression of immunosuppressive molecules such as interleukin (IL)-10 and programmed cell death 1 ligand 1 by these cells. They also effectively inhibit the maturation of dendritic cells and their ability to produce proinflammatory cytokines and to stimulate potent T-cell responses. Furthermore, MSCs inhibit the generation and proinflammatory properties of CD4+ T helper (Th)1 and Th17 cells, while they promote the proliferation of regulatory T cells and their inhibitory capabilities. MSCs also impair the expansion, cytokine secretion, and cytotoxic activity of proinflammatory CD8+ T cells. Moreover, MSCs inhibit the differentiation, proliferation, and antibody secretion of B cells, and foster the generation of IL-10-producing regulatory B cells. Various cell membrane-associated and soluble molecules essentially contribute to these MSC-mediated effects on important cellular components of innate and adaptive immunity. Due to their immunosuppressive properties, MSCs have emerged as promising tools for the treatment of inflammatory disorders such as acute graft-versus-host disease, graft rejection in patients undergoing organ/cell transplantation, and autoimmune diseases.

show abstract

Current Concepts on 6-sulfo LacNAc Expressing Monocytes (slanMo)

Cited by 39 publications

References 135 publications

Phototherapy in the perspective of the chronicity of psoriasis

Phototherapy in the perspective of the chronicity of psoriasis

Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy

Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update

Contact Info

Product

Resources

About